Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 17/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | APAF1 | O14727 | 1/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16296892 | 0.87 | NAT1 (0.63) | NAT1GAAMAPTMEN1LMNA | |
| SCHEMBL1815994 | 0.79 | MAPT (0.71) | NAT1GAAMAPTMEN1LMNA | |
| SCHEMBL16303882 | 0.79 | NAT1 (1.00) | NAT1GAAMAPTMEN1LMNA | |
| SCHEMBL16296667 | 0.78 | NAT1 (0.81) | NAT1GAAMAPTMEN1LMNA | |
| SCHEMBL16296725 | 0.78 | MAPT (0.57) | MAPTMEN1LMNAKMT2ATDP1 | |
| SCHEMBL16297044 | 0.77 | NAT1 (0.70) | NAT1GAAMAPTMEN1LMNA | |
| SCHEMBL8930994 | 0.74 | ADORA2A (0.68) | NAT1GAAMAPTMEN1LMNA | |
| SCHEMBL16296830 | 0.74 | THRB (0.51) | MAPTMEN1LMNAKMT2ATDP1 | |
| SCHEMBL12653233 | 0.71 | NAT1 (0.76) | NAT1GAAMAPTMEN1LMNA | |
| SCHEMBL16297097 | 0.71 | MAPT (0.81) | GAAMAPTMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220128562-A1 | BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF | UNIVERSITY OF KANSAS | 2022-04-28 | — | — | US | disclosed |
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | UNIVERSITY OF KANSAS | 2017-11-23 | — | — | US | disclosed |
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | UNIVERSITY OF KANSAS | 2017-11-23 | — | — | US | disclosed |
| US-9745261-B2 | Inhibitors of the MITF molecular pathway | THE GENERAL HOSPITAL CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745261-B2 | Inhibitors of the MITF molecular pathway | THE GENERAL HOSPITAL CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE BROAD INSTITUTE, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE BROAD INSTITUTE, INC. | 2016-05-12 | — | — | US | disclosed |
| EP-3007688-A2 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | The General Hospital Corporation (US) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014201016-A2 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014201016-A2 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | MITF, TFEB, TYR | NAT1 356/4885GAA 818/4885MAPT 4100/4885 |
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | MITF, TFEB, TYR | NAT1 381/4885GAA 789/4885MAPT 4092/4885 |
| US-20220128562-A1 | BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF | NQO1, KEAP1, NFE2L2 | NAT1 457/4885GAA 3678/4885MAPT 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.